BridgeBio Common Stock Total Equity from 2010 to 2024
| BBIO Stock | USD 28.01 0.84 2.91% |
Common Stock Total Equity | First Reported 2010-12-31 | Previous Quarter 141.3 K | Current Value 134.2 K | Quarterly Volatility 2 M |
Check BridgeBio Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BridgeBio main balance sheet or income statement drivers, such as Interest Income of 18.9 M, Depreciation And Amortization of 6.2 M or Interest Expense of 85.4 M, as well as many exotic indicators such as Price To Sales Ratio of 742, Dividend Yield of 4.0E-4 or Days Sales Outstanding of 92.54. BridgeBio financial statements analysis is a perfect complement when working with BridgeBio Pharma Valuation or Volatility modules.
BridgeBio | Common Stock Total Equity |
Latest BridgeBio Pharma's Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of BridgeBio Pharma over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. BridgeBio Pharma's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BridgeBio Pharma's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
BridgeBio Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 2,314,502 | |
| Geometric Mean | 989,914 | |
| Coefficient Of Variation | 86.66 | |
| Mean Deviation | 1,740,197 | |
| Median | 3,411,000 | |
| Standard Deviation | 2,005,773 | |
| Sample Variance | 4T | |
| Range | 6.5M | |
| R-Value | (0.68) | |
| Mean Square Error | 2.3T | |
| R-Squared | 0.46 | |
| Significance | 0.01 | |
| Slope | (303,938) | |
| Total Sum of Squares | 56.3T |
BridgeBio Common Stock Total Equity History
About BridgeBio Pharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include BridgeBio Pharma income statement, its balance sheet, and the statement of cash flows. BridgeBio Pharma investors use historical funamental indicators, such as BridgeBio Pharma's Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although BridgeBio Pharma investors may use each financial statement separately, they are all related. The changes in BridgeBio Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BridgeBio Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on BridgeBio Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in BridgeBio Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 141.3 K | 134.2 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of BridgeBio Pharma Correlation against competitors. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for BridgeBio Stock analysis
When running BridgeBio Pharma's price analysis, check to measure BridgeBio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Pharma is operating at the current time. Most of BridgeBio Pharma's value examination focuses on studying past and present price action to predict the probability of BridgeBio Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Pharma's price. Additionally, you may evaluate how the addition of BridgeBio Pharma to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is BridgeBio Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.23) | Revenue Per Share 1.291 | Quarterly Revenue Growth 114.619 | Return On Assets (0.40) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.